Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates

Rhea-AI Summary

Insulet (NASDAQ: PODD), a leader in tubeless insulin pump technology, announced the launch of its Omnipod 5 Automated Insulin Delivery System in France, now available for people aged two and older and compatible with the Dexcom G6 CGM. The French National Authority for Health has granted reimbursement status for the system.

In the U.S., Insulet has commenced the full commercial launch of Omnipod 5 with Dexcom G7 integration, offering users a new Pod compatible with both Dexcom G6 and G7 sensors. Additionally, the Omnipod 5 App for iPhone has begun a market release, initially integrating with Dexcom G6, with future updates to include Dexcom G7 compatibility.

These milestones reflect Insulet's commitment to expanding access to its innovative diabetes management technology globally.

Positive

• Launch of Omnipod 5 in France, expanding market reach.
• Reimbursement status granted by the French National Authority for Health.
• Full commercial launch of Omnipod 5 with Dexcom G7 integration in the U.S.
• market release of Omnipod 5 App for iPhone in the U.S.

Negative

• None.

Insights

Medical Research Analyst

From a medical perspective, the launch of Omnipod 5 in France and the U.S. reveals significant advancements for diabetes management. The integration with Dexcom G6 and G7 in the U.S. enhances the utility of continuous glucose monitoring (CGM) systems. The Omnipod 5's ability to proactively regulate blood glucose levels by communicating with these sensors potentially improves patient outcomes by reducing instances of hypoglycemia and hyperglycemia. This is particularly critical for patients managing type 1 diabetes, where maintaining tight glucose control is essential to preventing long-term complications.

The clinical results cited, including lower A1c levels and improved time in range metrics, underscore the efficacy of the system. These outcomes can lead to better overall health for patients, reducing their dependency on traditional insulin delivery methods and fingerstick tests, thus enhancing their quality of life.

For retail investors, these developments suggest that Insulet is at the forefront of innovative diabetes care technologies. This can potentially lead to higher adoption rates, increased market share and stronger revenue growth for the company in the long term.

Tech Expert

The integration of the Omnipod 5 with both the Dexcom G6 and G7 sensors and the introduction of the iPhone app in the U.S. marks a significant technological progression. The shift towards smartphone-controlled insulin delivery represents a broader trend in the med-tech industry towards user-friendly, app-based solutions.

Having an iPhone app increases accessibility and ease of use for tech-savvy patients, which may lead to higher adherence rates and better patient outcomes. Furthermore, the compatibility with both Android and iOS platforms ensures that a broad user base can benefit from the technology, potentially increasing market penetration.

For investors, this technological innovation positions Insulet as a leader in digital health, likely driving future growth and strengthening their competitive edge in the insulin delivery market.

Financial Analyst

From a financial standpoint, the expansion into France and the U.S. product updates are poised to have a positive impact on Insulet's revenue streams. France's reimbursement status from the French National Authority for Health makes Omnipod 5 accessible to a larger patient base, which can drive sales in the European market.

The full commercial launch of Omnipod 5 with Dexcom G7 integration in the U.S. and the limited market release of the iPhone app are strategic moves to capture a larger share of the lucrative U.S. diabetes care market. These updates can translate into increased demand and higher sales figures.

Investors should note that broadening product availability and enhancing functionality are likely to boost Insulet's financial performance in both the short and long term. This could lead to upward revisions in earnings estimates and potentially a positive impact on the stock price.

• Omnipod 5, the world’s first tubeless automated insulin delivery (AID) system integrated with Dexcom G6, is now available in France
• Full commercial launch of Omnipod 5 with Dexcom G7 integration has commenced in the U.S.
• Omnipod 5 App for iPhone begins limited market release in the U.S.

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well as the limited market release of the Omnipod 5 App for iPhone.

“Achieving these milestones demonstrates our Company’s ongoing commitment to making our life-changing diabetes technology more accessible around the world,” said Jim Hollingshead, President and Chief Executive Officer. “With our recent expansion into France, Omnipod 5 is now accessible to the majority of our European customers. The integration of Dexcom G7 and the iPhone mobile app in the U.S. enables more options for those considering Omnipod 5 for their insulin delivery.”

Omnipod 5, the #1 prescribed and #1 favorite pump¹ in the U.S., is the first tubeless AID system that communicates with a continuous glucose monitor (CGM) and proactively corrects for highs and protects against lows, day and night. The waterproof² Pod and mobile app control have been designed with the customer in mind aiming to deliver exceptional ease of use. Omnipod 5 has demonstrated strong clinical results including lower A1c and improved time in range, while maintaining low time in hypoglycemia.^3,4

Omnipod 5 is Now Available in France

Omnipod 5 is now available in France to people with type 1 diabetes, ages two years or older, and is compatible with the Dexcom G6 CGM. Omnipod 5 recently received reimbursement status from the French National Authority for Health (Haute Autorité de Santé or HAS), making the system accessible to eligible people with type 1 diabetes.

“Omnipod 5 has already had a huge impact on health outcomes for those with type 1 diabetes. Today, we celebrate the introduction of Omnipod 5 in France, which we know has been eagerly anticipated,” said Patrick Crannell, Senior Vice President and International General Manager. “The results of our studies demonstrate that Omnipod 5 improves quality of life and represents a significant advancement in diabetes management.”

Omnipod 5 with Dexcom G7 (U.S.)

Insulet has begun the full commercial launch of Omnipod 5 with Dexcom G7 sensor integration in the U.S. Omnipod 5 is the only tubeless automated insulin delivery system that connects with both Dexcom G6 and G7 sensors, providing more choice for people with type 1 diabetes.

New Omnipod 5 customers will receive the updated starter kit, which includes a new Pod compatible with both Dexcom G6 and Dexcom G7 and a Controller now featuring user-selectable Dexcom CGM options to connect to the Pod. Insulet is in the process of communicating to existing Omnipod 5 users in the U.S. that their free remote software update is anticipated to be available the week of July 29.

Omnipod 5 App for iPhone (U.S.)

Insulet recently started a limited market release of its highly anticipated Omnipod 5 App for iPhone in the U.S. Insulet is the first and only company to offer a tubeless AID system with full control from a compatible Android or iOS smartphone.

The Omnipod 5 App for iPhone will launch first with Dexcom G6 integration. Insulet will communicate broadly to the diabetes community when the Omnipod 5 App for iPhone is available on the App Store. The Omnipod 5 App for iPhone with Dexcom G7 will follow in the future.

To stay informed of Insulet’s progress with future innovation, visit Omnipod.com/innovation. You may also speak with a member of the Insulet team in the Exhibit Hall at the American Diabetes Association’s 84th Scientific Sessions in Orlando, Florida, taking place Friday, June 21 through Monday, June 24. A full schedule of events and presentations is listed on Omnipod.com.

1USA 2023, Data on file.

2The Pod has an IP28 rating for up to 7.6 meters (25 feet) for 60 minutes. The Omnipod 5 controller is not waterproof. The Dexcom G6 sensor and transmitter are water-resistant and may be submerged under 2.4 meters (8 feet) of water for up to 24 hours without failure when properly installed.

3 Sherr JL, et al. Diabetes Care (2022). Study in 80 people with type 1 diabetes (T1D) aged 2 - 5.9 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

4 Brown et al. Diabetes Care (2021). Study in 240 people with T1D aged 6 - 70 years involving two weeks standard diabetes therapy followed by three months Omnipod 5 use in Automated Mode.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be fully controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit insulet.com and omnipod.com.

©2024 Insulet Corporation. Omnipod is a registered trademark of Insulet Corporation. All rights reserved. Dexcom is a registered trademark of Dexcom, Inc. and used with permission. All other trademarks are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620692555/en/

Investor Relations:

Deborah R. Gordon

Vice President, Investor Relations

(978) 600-7717

dgordon@insulet.com

Media:

Angela Geryak Wiczek

Senior Director, Corporate Communications

(978) 932-0611

awiczek@insulet.com

Source: Insulet Corporation

FAQ

What recent launches has Insulet announced?

Insulet recently launched Omnipod 5 in France and commenced a full commercial launch of Omnipod 5 with Dexcom G7 integration in the U.S.

When is the Omnipod 5 App for iPhone expected to be widely available?

The Omnipod 5 App for iPhone has begun a market release in the U.S., with broader availability to be communicated by Insulet.

What is the significance of Omnipod 5's launch in France?

Omnipod 5's launch in France marks its availability to people with type 1 diabetes aged two and older, with reimbursement status granted by the French National Authority for Health.

How does Omnipod 5 enhance diabetes management?

Omnipod 5 provides a tubeless automated insulin delivery system integrated with the Dexcom G6 or G7 CGMs, offering proactive glucose management and improved clinical outcomes.

What stock symbol represents Insulet ?

Insulet is represented by the stock symbol PODD.